All Patients with pre-op data | Patients with follow up data | |
---|---|---|
N = 203 | N = 183 | |
Hamada Grade | ||
Stage 2 | 55 (27.1%) | 49 (26.8%) |
Stage 3 | 43 (21.2%) | 41 (22.4%) |
Stage 4a; Stage 4b; Stage 5 | 105 (51.7%) | 93 (50.8%) |
Age | ||
Mean (SD) | 74.9 (6.7) | 74.7 (6.5) |
Range | 41.9 to 91.6 | 41.9 to 87.5 |
Gender | ||
Female | 134 (66.0%) | 122 (66.7%) |
Male | 69 (34.0%) | 61 (33.3%) |
Dominance | ||
Dominant | 185 (91.1%) | 166 (90.7%) |
Non dominant | 18 (8.9%) | 17 (9.3%) |
ASA grade | ||
1 | 15 (7.4%) | 13 (7.1%) |
2 | 22 (10.8%) | 20 (10.9%) |
3 | 69 (34.0%) | 66 (36.1%) |
4 and 5 | 97 (47.8%) | 84 (45.9%) |
ASES | ||
Mean (SD) | 20.3 (12.9) | 20.8 (12.8) |
Range | 0.0 to 63.3 | 0.0 to 63.3 |
Constant | ||
Mean (SD) | 24.6 (13.2) | 25.3 (13.2) |
Range | 3.0 to 67.0 | 3.0 to 67.0 |